Tag Archive for: apalutamide
Triplet therapy shows strongest survival benefit in mHSPC with visceral disease
/0 Comments/in Review/by MaxReal-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/0 Comments/in Retrospective studies/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxRedefining Prostate Cancer Care: The LIBERTAS Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/0 Comments/in Observational, Retrospective studies/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/0 Comments/in Observational, Post-hoc, Retrospective studies/by MaxEarly PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer
/0 Comments/in Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025